Skip to main content
. Author manuscript; available in PMC: 2021 Feb 25.
Published in final edited form as: Methods Mol Biol. 2016;1354:39–47. doi: 10.1007/978-1-4939-3046-3_3

Fig. 3.

Fig. 3

The capsid drug CPIPB (4-{2-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-1-[3-(1H-imidazol-1-yl)propyl]-1H-benzimidazol-5-yl}benzoic acid dihydrochloride) stabilizes in vitro-assembled HIV-1 CA-NC complexes. The stability of HIV-1 CA-NC complexes in destabilization buffer using increasing concentrations of the drug CPIPB was measured. CPIPB has been shown previously to strongly increase HIV-1 capsid crystallization and competes with the novel restriction factor M×B for binding to the HIV-1 capsid [29, 30].